Journal of the American Society of Hypertension
Review ArticleReview of the state of renal nerve ablation for patients with severe and resistant hypertension
Introduction
Inadequate blood pressure (BP) control is the most common attributable risk for death worldwide, being responsible for 62% of cerebrovascular disease and 49% of ischemic heart disease.1 Despite the availability of several effective drugs for control of BP, approximately 50% of patients have suboptimal control of their BP.2 Resistant hypertension has been defined as failure to achieve goal BP when a patient adheres to maximum tolerated doses of three antihypertensive drugs, including a diuretic.3 It is estimated that the prevalence of resistant hypertension in the U.S. varies from 8% to 20%.4, 5 Until recently, therapeutic options for patients with resistant hypertension were limited to drug therapies. However, insights into the pathophysiology of resistant hypertension and understanding of the role of the sympathetic nervous system have led to the development of renal nerve denervation as a potential management option.
Section snippets
Early Experience with Lumbar Sympathectomy for the Treatment of Hypertension
Recognizing that the sympathetic nervous system played an important role in the pathogenesis of hypertension led to a surgical approach known as radical lumbo-dorsal splanchnicectomy to disrupt catecholamine discharges.6 This technique, developed by Smithwick in 1938, lowered BP and reduced mortality, but at the cost of severe and incapacitating side effects.6, 7 Several uncontrolled trials of surgical sympathectomy demonstrated profound improvement in BP control along with reduction in cardiac
Renal Sympathetic Nervous System
Sympathetic innervation of the kidneys plays a major role in the pathogenesis of hypertension through modulation of renin secretion, glomerular filtration rate, and renal absorption of sodium.11, 12 The preganglionic sympathetic neurons originate in the intermediolateral column of the spinal cord at thoracic and lumbar levels (T10 to T12, L1 to L2) and extend via splanchnic nerves to synapse with the postganglionic neurons in the pre- and paravertebral ganglia.13 The renal sympathetic system
Clinical Rationale for Renal Denervation
The concept of renal denervation was initiated from observations made in patients undergoing nephrectomy or renal transplantation and animal models of renal sympathectomy. Increased sympathetic activity has been demonstrated in patients with end-stage renal disease requiring dialysis and normalization of that activity following bilateral nephrectomy.19 In contrast, sympathetic overactivity persists in patients whose native diseased kidneys are not removed, further supporting the hypothesis that
Technical Development of Renal Sympathetic Denervation
Sobotka and Esler pioneered the technique of percutaneous renal sympathetic denervation, and performed the first studies of catheter-based renal nerve ablation using radiofrequency (RF) energy.23 The catheter-based approach was developed to directly target the sympathetic nerves adjacent to the renal artery. The procedure involves insertion of an endovascular catheter under fluoroscopic guidance via the femoral artery using a 6F or 8F guide and advancing it towards the distal renal artery.
RF Ablation (RFA) Technology
Catheter-based renal denervation for drug resistant hypertension using a standard electrophysiology catheter has already demonstrated significant reductions in clinic BP in patients resistant to drug therapy.25 These data have paved the way for development of numerous proprietary systems that are presently undergoing clinical assessment. At present, four systems using RFA technology have been approved for phase 3 clinical study programs in the U.S., Europe, and other countries around the world:
Ultrasonic Ablation Technology
Ultrasound energy consists of high-frequency sound waves that are emitted circumferentially by the cylindrical transducer. These sound waves pass through the surrounding fluids and generate frictional heating of soft tissues, resulting in a temperature increase and nerve damage at depth. It induces a targeted injury pattern to the renal sympathetic nerves within the adventitia of renal artery.
Bullfrog Microinfusion Catheters
The Mercator Bullfrog microinfusion catheter (Mercator MedSystems Inc, San Leandro, CA) is a catheter-guided system designed to inject therapeutic agents directly, non-systemically, and safely through blood vessel walls into adventitial tissues. It has received U.S. Food and Drug Administration 510(k) clearance. Thus far, the sympatholytic agent guanethidine has been studied for injection in the renal arteries. Given locally, guanethidine induces autonomic denervation directly and through an
Safety Concerns for Renal Nerve Ablation in Humans
All the modalities available for renal sympathetic nerve denervation either approved by European regulatory agencies or in the final stages of development and testing use intravascular techniques for delivery of energy. Besides any physiological changes occurring due to renal denervation, being an invasive procedure, complications may occur due to the procedure itself. There were two procedure-related complications in the initial cohort of Symplicity 1 trial: one renal artery dissection related
Heart Failure
The sympathetic nervous system is the driving force behind several compensatory pathophysiologic processes in cardiovascular disorders. For example, neurohumoral activation is a negative prognostic marker in chronic heart failure, and the use of beta-blockers significantly reduces cardiovascular morbidity and mortality.38 High renal sympathetic activity in heart failure patients on treatment with beta-adrenergic blockade has shown to predict early death.39 Of interest, studies in animal models
Potential Limitations of Renal Denervation
While studies have shown beneficial effects of the procedure, there are no long-term controlled data on the efficacy or sustainability of the procedure. There is also limited data on the impact of renal denervation on out-of-office BP. Data from the Symplicity HTN-2 trial shows that renal denervation might not reduce ambulatory BP nearly as effectively as the doctor's office BP. Data from 10 European hypertension clinics within the European network coordinating research on renal denervation
Conclusions
Treatment of drug-resistant hypertension has entered into an interesting historical phase with the emergence of renal nerve ablation therapy. Current evidence from the phase I and 2 clinical trials suggests that the use of catheter-based RFA of renal nerves could be successful in a small, but important subset of patients with severe and resistant hypertension. However, the mechanisms governing BP control are complex and multi-factorial. Long-term safety and efficacy data using controlled
References (62)
- et al.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Lancet
(2009) - et al.
First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH- Pilot study
Int J Cardiol
(2013) - et al.
Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension
J Am Coll Cardiol
(2012) - et al.
Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension
J Am Coll Cardiol
(2012) - et al.
Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension
J Am Coll Cardiol
(2011) - et al.
A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension
J Am Coll Cardiol
(2012) World Health Report 2002: Reducing risks, promoting healthy life
(2002)- et al.
Hypertension treatment and control in five European countries, Canada, and the United States
Hypertension
(2004) - et al.
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research
Circulation
(2008) - et al.
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988–2008
Circulation
(2011)
Prevalence of resistant hypertension in the United States, 2003–2008
Hypertension
Effect of sympathectomy on blood pressure in hypertension: a review of 13 years' experience of the Massachusetts General Hospital
JAMA
Hypertension and associated cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy
JAMA
Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension
Ann Surg
Surgery in hypertension
Lancet
Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy
Ann Surg
Neural control of renal function
Physiol Rev
Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system
Circulation
Anatomy of the renal innervation: intrarenal aspects and ganglia of origin
Can J Physiol Pharmacol
The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover
Hypertension
The sympathetic system and hypertension
Am J Hypertens
Functional role of renal afferents
Physiol Rev
Renal afferents and hypertension
Curr Hypertens Rep
Renorenal reflexes: neural components of ipsilateral and contralateral renal responses
Am J Physiol
Sympathetic overactivity in patients with chronic renal failure
N Engl J Med
Sympathetic nerve activity in end-stage renal disease
Circulation
Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys
Transplantation
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure
N Engl J Med
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation
Eur Heart J
Catheter- based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter
EuroIntervention
Cited by (14)
The add-on effect of a Chinese herbal formula for patients with resistant hypertension: Study protocol for a pilot cohort study
2015, Journal of Integrative MedicineSYMPLICITY: Not all that simple
2014, Kidney InternationalDetection, evaluation, and treatment of severe and resistant hypertension Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, USA, October 10th 2013
2014, Journal of the American Society of HypertensionCitation Excerpt :Additionally, following the completion of primarily uncontrolled studies in Europe and Australia, RDN has been performed in clinical practice in these regions when secondary forms of hypertension and pseudo-resistance, such as medication nonadherence, or white-coat hypertension based on ambulatory blood pressure (BP) monitoring (ABPM), have been excluded. Catheter-based radiofrequency ablation technology to disrupt both efferent and afferent sympathetic renal nerves (RDN) has become relatively widespread outside the US for the management of RH.2 Clinical study data available thus far have been obtained primarily in patients whose RH is defined as clinic systolic BPs (SBPs) of ≥160 mm Hg or ≥150 mm Hg in patients with type 2 diabetes mellitus, despite pharmacologic treatment with at least three antihypertensive drugs at maximally tolerated doses, one of which must be a thiazide or loop diuretic.
Update From the Field of Renal Sympathetic Denervation: A Focus on Safety Nomenclature Considerations
2017, Therapeutic Innovation and Regulatory ScienceControversies Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United Kingdom Centers
2016, Journal of Clinical Hypertension